Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Besse

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
Cancer Treatment Reviews|November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategiesD Miliziano, C Sciortino, S Manglaviti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancerB Besse, N Leighl, J Bennouna, et al.
Lung Cancer (Amsterdam, Netherlands)|July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave RoussyM Kossai, B Duchemann, C Boutros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerE Pailler, N Auger, C R Lindsay, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?M Macerelli, C Caramella, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcomeJ-P Spano, F Andre, L Morat, et al.
Lung Cancer (Amsterdam, Netherlands)|January 1, 2021
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitorsB Abbar, V De Castelbajac, P Gougis, et al.
Respiratory Medicine and Research|September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapyC Lefebvre, E Martin, L E L Hendriks, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
Cancer Treatment Reviews|November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategiesD Miliziano, C Sciortino, S Manglaviti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancerB Besse, N Leighl, J Bennouna, et al.
Lung Cancer (Amsterdam, Netherlands)|July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave RoussyM Kossai, B Duchemann, C Boutros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerE Pailler, N Auger, C R Lindsay, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?M Macerelli, C Caramella, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcomeJ-P Spano, F Andre, L Morat, et al.
Lung Cancer (Amsterdam, Netherlands)|January 1, 2021
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitorsB Abbar, V De Castelbajac, P Gougis, et al.
Respiratory Medicine and Research|September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapyC Lefebvre, E Martin, L E L Hendriks, et al.
Pageof 14